Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double- Blind, Controlled, Parallel-group, Multicenter Study to Assess the Safety and Immunogenicity of Transitioning to GP2013 or Re-treatment With Rituxan® or MabThera® in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®

NCT02514772 is registered in ClinicalTrials.gov with Sandoz as lead sponsor.

NCT NCT02514772
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02514772 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double- Blind, Controlled, Parallel-group, Multicenter Study to Assess the Safety and Immunogenicity of Transitioning to GP2013 or Re-treatment With Rituxan® or MabThera® in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®
Lead sponsor
Sandoz
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2015
Completion date
October 31, 2016
Enrollment
107 (actual)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis